TG Therapeutics (TGTX) Bɛn Dɛŋɛn Akɔc
AI forecast: TGTX
AI ekek aŋok wɛlɛɛl bɛn bɛn lɔŋɔŋ, bɛn bɛn cɔlɔŋ, kɛ bɛn bɛn cɔlɔŋ. Cɔkɔkɔkɔ cɔlɔŋ bɛn bɛn lɔŋɔŋ. Aŋok wɛlɛɛl aŋok wɛlɛɛl, aŋok wɛlɛɛl aŋok wɛlɛɛl.
Bɛn cɔk ɛcɔk 6
Premium shows the AI's price targets for 1 day, 1 week and 1 month for this and every other stock.
Unlock Premium🔒 Nyɛn cɔk aya bɛn
Ditëëk ë bɛ̈ɛ̈r ë cë lɔ – ditëëk ë cë lɔ kee aköl aköl ë bɛ̈ɛ̈r ë cë lɔ – aye Premium.
Unlock PremiumBɛn kɔc ke bɛn
TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the acquisition, development, and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved diseases. The company is developing two treatments for hematologic malignancies, specifically relapsed and refractory non-Hodgkin lymphoma.